Introduction: A dysregulated intestinal T cell response is presumed in patients with inflammatory bowel disease [IBD]. In this longitudinal study, we investigated the changes in intestinal T lymphocyte subsets in IBD at first presentation and over time during endoscopic active or inactive disease, and relate them to disease activity and outcome. Methods: We included 129 newly diagnosed patients (87 Crohn´s disease [CD], 42 ulcerative colitis [UC]) and 19 healthy controls [HC]. Follow-up biopsy specimens were analysed from 70 IBD patients. Immunophenotyping of specimens was performed by flow cytometry identifying lymphocyte subpopulations. Results: IBD patients at diagnosis displayed higher percentages of CD4 T + cells, Tregs, and central memory T cells [T CM ] and with lower percentages of CD8 and CD103 T lymphocytes than HC. Follow-up specimens of patients with endoscopic inactive disease showed T cell subset recovery comparable to HC. Endoscopic active disease at follow-up coincided with T cell subsets similar to those at diagnosis. In UC, lower baseline percentages of CD3 cells was associated with milder disease course without the need of an immunomodulator, whereas in CD, higher baseline percentages of CD4 and Tregs were associated with complicated disease course. Conclusions: The intestinal T cell infiltrate in IBD patients with active endoscopic disease is composed of increased percentages of CD4 + T cells, Tregs, and T CM , with lower percentages of CD8 + T cells and CD103 + T cells, compared with HC and endoscopic inactive IBD. Baseline percentages of CD3, CD4, and Tregs were associated with disease outcome. Further research is needed to demonstrate the predictive value of these lymphocyte subsets.
Intestinal T Cell Profiling in Inflammatory Bowel
, with a chronic and relapsing character. Diagnosis is based on a combination of internationally accepted clinical, endoscopic, histological, and radiological findings. 1, 2 Incidence is increasing, and disease burden is substantial due to the chronic nature and generally young age at onset of disease. 3 Disease presentation and course are heterogeneous and unpredictable. Approximately 50% of CD patients are expected to develop disease complications over time, requiring aggressive medical therapy such as [biologic] immunomodulators or surgery. 4, 5 In CD patients, clinical determinants associated with a complicated disease course are younger age [< 40 ], perianal or stricturing disease, involvement of the upper gastrointestinal tract, penetrating disease, and smoking. 6, 7 Colectomy is considered a solid endpoint for disease severity in UC, and is required in approximately 10% of patients in the first 10 years of disease. Extensive colitis, as well as severe systemic symptoms were shown to be predictors of colectomy. [8] [9] [10] Guidelines for the choice of treatment modality in IBD are still generic and historically based, without much focus on the individual patient. Biomarkers that can predict disease course or response to therapy would help in focusing on the individual patient. Until now, results have been somewhat disappointing. Some efforts have been made in a study describing CD8 + T cell transcriptional signatures associated with frequently relapsing disease in IBD patients. 11 Recently, a list of key research priorities regarding IBD treatment was compiled, including selection of patients for optimal treatment strategies. 12 Identifying biomarkers that relate to disease behaviour and response to therapy would help in this process.
The first step in this process would be to identify potential biomarkers in IBD patients and to analyse the behaviour of these candidate biomarkers in patients over time. A dysregulated T lymphocyte response is often implicated as key mediator of chronic inflammation in IBD. 13, 14 This is supported by the growing number of successful therapeutic approaches targeting T cells in IBD patients, such as: thiopurines, inducing T cell apoptosis; anti-α4β7, targeting the traffic of gut homing T cells; and anti-IL12/23 p40, interfering with T helper 1 [Th1] and Th17 lymphocytes. 15 Most research on T lymphocytes in IBD has focused on activated CD4 + T effector lymphocytes (Th1, Th2, Th17, and regulatory T cells [Tregs] ). 13 The research on T lymphocytes in IBD was mainly based on cytokines detected in the mucosa of longstanding IBD patients and animal models. Instead of an overwhelming increase of effector memory T cells [T EM ], we previously identified newly diagnosed patients with increased percentages of naïve T lymphocytes [T N ] and central memory T lymphocytes [T CM ] in their inflamed gut mucosa. 16 Furthermore, it was shown that patients had higher percentages of Tregs and lower percentages of CD103 + T cells at diagnosis, when compared with healthy controls. Differences in mucosal T cell subsets between IBD patients at diagnosis might have predictive value for response to different therapeutic agents. Our hypothesis is that intestinal mucosal T lymphocyte subsets may be potential biomarkers for disease course in IBD. Therefore, the primary aim of this longitudinal study was to investigate the changes of intestinal mucosal T lymphocyte subsets in IBD patients at diagnosis and during follow-up, in both presence and absence of endoscopic inflammation. A secondary aim was to study these subsets in relation to disease course over time.
Methods

Study population
Patients suspected of IBD were prospectively enrolled at the outpatient clinic of the Crohn and Colitis Centre of Rijnstate Hospital Arnhem, The Netherlands. After standardised work-up including clinical, endoscopic, histopathological and, when applicable, radiological evaluation, all patients met the accepted international diagnostic criteria of CD or UC. 1, 2 Patients were recruited before initial diagnostic ileocolonoscopy, enrolled after IBD was diagnosed, and subsequently followed in their clinical course. During the initial ileocolonoscopy, multiple biopsy specimens were taken for histopathological analysis and immunophenotyping by flow cytometry analysis. Lymphocyte subsets at baseline, for part of the IBD patients included in this study and healthy controls [HC], were previously described. 16 These groups were expanded with newly diagnosed patients and HC. Follow-up endoscopy was performed as part of standard care, taking additional biopsy specimens for immunophenotyping.
Healthy controls underwent ileocolonoscopy for polyp surveillance and did not present endoscopic pathology. None of the healthy controls had any signs of IBD or other immune-mediated diseases.
Classification and definitions
Endoscopic severity of the disease at baseline and follow-up was assessed in CD by the simple endoscopy score for CD [SES-CD; ranging from < 4 to> 19] and in UC by the Mayo score [ranging from 0 to 3]. 17 Inactive disease was defined as endoscopic remission Disease phenotype [location and behaviour] at baseline and at latest follow-up was assessed according to the Montreal classification. 18 Clinical disease activity at baseline and follow-up was assessed using the Harvey-Bradshaw index for CD and the Montreal classification for UC. 18, 19 Overall use of and response to medication was recorded. In general, therapeutic management of IBD after diagnosis was done according to the step-up approach, as recommended by the Dutch guidelines. 20 In UC patients, topical and/or oral 5-aminosalicylate [5-ASA] was initiated as induction therapy. In case of a severe pancolitis or when induction with 5-ASA treatment failed, patients were treated with topical or systemic steroids. When UC patients were steroid refractory, anti-tumour necrosis factor [TNF] therapy was started. When patients were steroid dependent or had relapsing disease, a thiopurine was initiated and, in case of therapy failure or relapsing disease, anti-TNF treatment was initiated. Failure in either induction or maintenance of remission could lead to surgical escape therapy, i.e. colectomy. In CD patients, steroids were started as induction therapy. This was usually followed by the initiation of maintenance treatment [thiopurine derivates or methotrexate], especially in case of steroid-dependent disease. Anti-TNF therapy was initiated in case of steroid-refractory or steroid-dependent disease, or in case of extended perianal fistulising disease, usually in combination with a thiopurine derivate. If the disease did not respond to conventional treatment, resective surgery was considered. During relapse, escalation of maintenance treatment was considered.
We determined the highest treatment step in each patient, comparing 5-ASA, steroids, immunomodulator, anti-TNF, and resective surgery as measures of severity of the disease. UC patients only needing 5-ASA treatment, and/or a short initial treatment with steroids, were classified as mild disease. Moderate UC was defined as the use of thiopurines after 5-ASA failure, and severe UC as the need for anti-TNF, vedolizumab or colectomy. CD patients with a mild disease course only needed 5-ASA, steroids, and/or an immunomodulator.
Moderate CD was defined as the need for step-up treatment above an immunomodulator [for instance anti-TNF therapy] without meeting the criteria of severe disease. Severe disease in CD was defined as the occurrence of penetrating or stricturing disease, perianal fistulising disease with the need for anti-TNF initiation and/or surgical intervention, and CD-related resective surgery.
Tissue samples and cell preparation
Six intestinal biopsy specimens from IBD patients at baseline were obtained from the macroscopically most inflamed areas at primary diagnosis, before the initiation of any medical treatment. At followup endoscopy, six biopsy specimens were obtained from the macroscopically most inflamed areas or, when there was no inflammation, from the areas of inflammation at baseline. Regular histopathological analysis was performed at baseline and follow-up, as well as immunophenotyping of the mucosal lymphocyte populations. In healthy controls, six biopsy specimens were randomly obtained from ileal and colonic areas. Regular histopathological examination confirmed the absence of inflammation, and immunophenotyping of the mucosal lymphocyte populations was performed. Biopsy specimens meant for flow cytometry analysis were kept in phosphate-buffered saline solution at 2-8°C and processed within 8 h. Specimens were pooled and finely minced in Hanks'/1% bovine serum albumin using a 70-mm gaze and spatula followed by Ficoll density gradient centrifugation. The homogenate was resuspended, after washing, in 0.5 mL Hanks'/1% bovine serum albumin. The cell concentration of the mononuclear cell susupension was estimated by microscopic counting with a KOVA glasstic slide [Hycor Biomedical, Penicuik, UK]. 
Flow cytometry
Statistical analysis
All variables were tested for normality using the Shapiro-Wilk test. Categorical variables were expressed as numbers of patients and percentages and compared with chi-square or Fisher's exact test when necessary. Continuous variables were described as median and interquartile range [IQR] and compared with the Mann-Whitney U test. When more than two groups were compared, we used the Kruskal-Wallis test followed by the Dunn test when applicable. Paired data [baseline and follow-up percentages of lymphocyte subsets] were compared using the Wilcoxon matched-pairs signed-rank test. We performed hierarchical clustering analysis to discriminate the potential signature of inactive and active disease at follow-up, using the software R. 22 Multivariate analyses were performed using binary logistic regression to identify independent predictors of disease course. 
Ethical considerations
Written informed consent was obtained from each participating patient before any study-related procedure was performed. The procedures were performed in accordance with the Declaration of Helsinki. The regional medical ethics committee approved the study protocol [NL28761.091.09]. 
Results
Patient characteristics
Lymphocyte distribution at baseline in IBD patients compared with healthy controls
To determine if lymphocyte subsets' distribution in the inflamed gut was influenced by biopsy location, we compared lymphocyte subset percentages from CD patients with ileal location [n = 30], biopsy specimens being taken only from the inflamed ileum, with those with colonic location [n = 17], biopsy specimens being taken only from the inflamed colon. There were no statistical differences for any of the analysed lymphocyte subsets between ileal and colonic location in CD [Supplementary Table 2] .
For baseline intestinal lymphocyte populations of the endoscopic inactive and active disease group at follow-up, see Supplementary  Tables 5-7 [available as Supplementary data at ECCO-JCC online]; percentages at baseline were comparable among both groups.
We additionally performed a hierarchical cluster analysis to compare the lymphocyte subsets signature of patients with active endoscopic disease with those with inactive endoscopic disease at follow-up [ Figure 2] The percentages of T lymphocyte subsets in patients without endoscopic disease activity recovered to levels comparable to HC [ Figure 3 and 4, Table 3 ]. Medical treatment at the moment of the follow-up endoscopy was very different between patients. No statistical differences were found for lymphocyte subsets percentages when adjusting for the different regimens. However, no definite conclusions can be drawn about the effect of treatment modality on lymphocyte subsets, due to the small sample size per treatment regimen.
T cell maturation profiles at baseline and during follow-up
Previously, we distinguished four T cell maturation profiles in the intestinal mucosa of IBD patients [ Figure 5 ]. 16 At baseline, 71% of UC patients had a B profile with predominantly T CM , whereas CD patients were more heterogeneous [B in 34%, C in 30%, A in 17%, and D in 16%], and HC had mainly a C or D profile [47% and 37%, respectively, Figure 5 ]. T cell maturation profiles were not associated with disease phenotypes or course.
In patients with IBD with active endoscopic disease at followup endoscopy, 89% of patients with a B profile at baseline retained this profile at follow-up. Among patients with a C or D profile at baseline, 50% changed to an A or B profile when there was disease activity at follow-up endoscopy.
On the other hand, in IBD patients with inactive endoscopic disease at follow-up endoscopy, the A and B profile changed to C or D in 79% of patients. The change of profile from baseline to follow-up in patients with inactive disease at follow-up endoscopy was statistically significant [p = 0.014]. Patients with C or D profile at baseline maintained this profile largely when there was inactive endoscopic disease at follow-up [86%].
Predicting disease course in UC
We determined the association between baseline lymphocyte subsets and disease course in UC patients with a follow-up duration of longer than one year [n = 33, 79% of all UC patients]. Of these There were no associations between the percentages of lymphocyte subsets at baseline and the following disease outcomes: surgery, biologics, relapsing disease, or future disease severity.
Predicting disease course in CD
We determined the association between lymphocyte subsets at baseline and disease course in CD patients with a follow-up duration of longer than one year 
Discussion
In the present study, marked differences were demonstrated in intestinal T lymphocyte subset composition of IBD patients with active endoscopic disease when compared with HC and patients in with inactive endoscopic disease. IBD patients at diagnosis displayed higher percentages of CD4, Tregs, and T CM , with lower percentages of CD8 and CD103 T lymphocytes. Patients with active endoscopic disease at follow-up analysis maintained the same compositions of T cell subsets as at the moment of diagnosis, with even lower percentages of CD8 T lymphocytes. This confirms consistency of T cell subset composition in time. Follow-up biopsy specimens of IBD patients with inactive endoscopic disease showed recovery of these subsets to a T lymphocyte composition, comparable to HC. Lymphocyte subset percentages were associated with endoscopic disease activity. Furthermore, in UC, lower baseline percentages of CD3 cells were associated with a milder disease course without the need of step-up to an immunomodulator, whereas in CD, higher baseline percentages of CD4 and higher percentages of Tregs were associated with a more complicated disease course. There were no differences found between ileum and colon regarding lymphocyte subsets: the composition of subsets seems more disease related than location related. This is endorsed by the association of the different lymphocyte subsets with endoscopic disease activity. Differences in lymphocyte subsets were more pronounced in UC than in CD patients. This might be explained by the fact that UC is characterised by more continuous inflammation conveyed to the mucosa and submucosa, with high chances that biopsy specimens from these patients are abundantly inflamed, whereas in CD, biopsy samples might have been taken from the edge of an ulcer with partly uninflamed tissue.
Intestinal inflammation in IBD has been attributed to CD4 subsets, based on animal models and cytokine expression in the gut mucosa. 23 However, auto-reactive CD8 cells have also been suggested as instigators of the disease by destruction of epithelial cells, after which exposure to luminal antigens may attract and expand the CD4 lineage, exacerbating inflammation. 24 The imbalance that we found, of increased CD4 with decreased CD8 frequencies in active endoscopic IBD at baseline and follow-up, seems to represent a CD4 expansion over CD8, but cannot provide further information on the real instigators of disease. The imbalance was normalised in the endoscopically inactive mucosa of IBD patients in remission, approaching comparable frequencies to HC. The percentages CD8 and CD4 T cells that we found in the intestines of controls was consistent with a previous study in organ donors. 25 In our study in CD patients, higher baseline percentages of CD4 were associated with the development of Tregs are involved in the maintenance of intestinal homeostasis by suppressing abnormal responses to enteric antigens, by direct interaction with other cells, and through secretion of anti-inflammatory cytokines like TGF-beta and IL-10. 26 In this study, we showed that IBD patients have increased percentages of Tregs at diagnosis [always with active endoscopic disease] and when there is active endoscopic disease during follow-up, whereas percentages decrease significantly in the same patients at times of inactive endoscopic disease. Furthermore, in CD patients, higher baseline percentages of Tregs were associated with a more complicated disease course with strictures or penetration, and a trend was observed towards more abdominal surgeries. Lower baseline percentages of Tregs in CD patients were associated with a milder course, with steroids as highest treatment step. It is tempting to speculate about a hampered function of Tregs in CD to be compensated by numbers. Increased mucosal Treg frequencies have been shown in active IBD before. 27 This could represent active recruitment and local expansion of these cells, attempting to suppress inflammation. However, this expansion is apparently not sufficient to control inflammation, possible due to the still too small number of cells. Another explanation might be that their function is impaired by upregulation of Smad7 in IBD patients, which inhibits TGF-beta signalling, thereby impairing the suppression of T cell activation and proliferation but possibly also the differentiation of naïve T cells into Tregs. 28, 29 Finally, there is evidence that transformation of Tregs into proinflammatory Th17 cells could also contribute to uncontrolled inflammation. 26 We demonstrated that IBD patients with active endoscopic disease had lower percentages of CD103 + T lymphocytes compared with HC, and a significant increase in percentages of CD103 + T lymphocytes in patients with endoscopic inactive disease at followup endoscopy. CD103 is the integrin αE of αEβ7 expressed on several immune cell subsets, and its expression is thought to contribute to the retention of T lymphocytes within the mucosa. Our findings suggest a less prominent role for CD103 + T cells as pathogenic factor in IBD patients than previously assumed, as it was thought to be upregulated in active endoscopic disease. [30] [31] [32] Therefore, it would be very interesting to study the CD103 + cell subpopulations in more detail, with the upcoming development of anti-β7 treatment. The function of the αEβ7 + T lymphocytes needs to be further investigated. αEβ7 is present on tissue-resident memory T cells [T RM , mainly on CD8 + T cells] with an immunosurveillance and protective function. 33 Recently, lung-derived CD103 + T RM cells were shown to possess a gene expression programme associated with the inhibition of T cell activation, which might play a role in preventing excessive immunoreactivity.
34 αEβ7 + T lymphocytes might even be necessary to achieve or maintain remission in patients, and a definitive pathogenic role of these cells in IBD has not yet been shown. Thus, from a mechanistic point of view, its blockade remains questionable. 35 
Conclusion
The intestinal T cell infiltrate in IBD patients with active endoscopic disease is composed of increased CD4 + T cells, Tregs, and T CM , with lower percentages of CD8 + T cells and CD103 + T cells compared with HC and endoscopically inactive IBD. After patients entered endoscopic remission, the lymphocyte subset composition of the gut recovered to percentages comparable with HC. Baseline percentages of CD3, CD4, and Tregs were associated with disease outcome in this study. Further research is needed to demonstrate the predictive value of these lymphocyte subsets. Knowledge of intestinal immune subsets at baseline and during follow-up could guide the use of new drugs and should be incorporated in the early phases of drug development to identify predictors of response.
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